ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT04013880 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Loss of funding

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions

DRUG: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
DRUG: IDH-1 Inhibitor FT-2102

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]
[object Object]